The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1, cell cycle arrest through induction of cyclin-dependent kinase inhibitors

EMBO Journal

Volumn 15, Issue 11, 1996, Pages 2748-2759

  Cayrol, C ^a,b   Flemington, E K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Lab de Pharmacol de Toxicol Fond   (France)

Author keywords

EBV; Growth arrest; p53; pRB; Zta

Indexed keywords

HUMAN HERPESVIRUS 4; HUMAN PAPILLOMAVIRUS; TUMOR VIRUS;

CYCLIN DEPENDENT KINASE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME INHIBITION; EPITHELIUM CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; WART VIRUS;

CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; DNA; DNA-BINDING PROTEINS; GROWTH INHIBITORS; HELA CELLS; HERPESVIRUS 4, HUMAN; HUMANS; LEUCINE ZIPPERS; MICROTUBULE-ASSOCIATED PROTEINS; NASOPHARYNGEAL NEOPLASMS; RETINOBLASTOMA PROTEIN; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 0030011018     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1460-2075.1996.tb00635.x     Document Type: Article

References (38)

1. Alday,M.J., Sinclair,A., Parker,G., Crawford,D.H. and Farrell,P.J. (1995) Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J., 14, 1382-1391.
2. Becker,J., Leser,U., Marschall,M., Langford,A., Jilg,W., Gelderblom,H., Reichart,P. and Wolf,H. (1991) Expression of proteins encoded by Epstein-Barr virus trans-activator genes depends on differentiation of epithelial cells in oral hairy leukoplakia. Proc. Natl Acad. Sci. USA, 88, 8332-8336.
3. Cayrol,C. and Flemington,E.K. (1995) Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of TGF-βigh3 and TGF-β1 J. Virol., 69, 4206-4212.
4. Chang,Y.-N., Dong,D.L.-Y., Hayward,G.S. and Hayward,S.D. (1990) The Epstein-Barr virus Zta transactivator: a member of the bZIP family with unique DNA binding specificity and dimerization domain that lacks the characteristic heptad leucine zipper motif. J. Virol., 64, 3358-3369.
5. Chi,T. and Carey,M. (1993) The ZEBRA activation domain: modular organization and mechanism of action. Mol. Cell. Biol., 13, 7045-7055.
6. Chowdary,D.R., Dermody,J.J., Jha,K.K. and Ozer,H.L. (1994) Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol. Cell. Biol., 14, 1997-2003.
7. Coffman,R.L., Lebman,D.A. and Shrader,B. (1989) Transforming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J. Exp. Med., 170, 1039-1044.
8. Cohen,J.I., Wang,F., Mannick,J. and Kieff,E. (1989) Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl. Acad. Sci. USA, 86, 9558-9562.
9. Countryman,J., Jensen,H., Seibel,R., Wolf,H. and Miller,G. (1987) Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J. Virol., 61, 3672-3679.
10. Datto,M.B., Li,Y., Panus,J.F., Howe,D.J., Xiong,Y. and Wang,X.-F. (1995) Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA, 92, 5545-5549.
11. Davies,R., Hicks,R., Crook,T., Morris,J. and Vousden,K.H. (1993) HPV16 E7 associates with a histone HI kinase activity and p 107 through sequences necessary for transformation. J. Virol., 67, 2521-2528.
12. 1 arrest. Cell, 76, 1013-1023.
13. Dyson,N., Howley,P.M., Munger,K. and Harlow,E. (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science, 143, 934-936.
14. El-Diery,W.S., Tokino,T., Velculescu,V.E., Levy,D.B., Parsons,R., Trent,J.M., Lin,D., Mercer,W.E., Kinzler,K.W. and Vogelstein,B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
15. Rickinson,A.B. (1986) Cellular immunological responses to infection by the virus. In Epstein,M.A. and Achong,B.G. (eds). The Epstein-Barr Virus: Recent Advances. William Heinemann, London, pp. 75-125.
16. Sarnow,P., Ho,Y.S., Williams,J. and Levine,A.J. (1982) Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell, 28, 387-394.
17. Scheffner,M., Werness,B.A., Huibregtse,J.M., Levine,A.J. and Howley,P.M. (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63, 1129-1136.
18. Scheffner,M., Munger,K., Byrne,J.C. and Howley,P.M. (1991) The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl Acad. Sci. USA, 88, 5523-5527.
19. Schepers,A., Pich,D. and Hammerschmidt,W. (1993) A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus. EMBO J., 12, 3921-3929.
20. Shadan,F.F., Cowsert,L.M. and Billarreal,L.P. (1994) n-Butyrate, a cell cycle blocker, inhibits the replication of polyomaviruses and papillomaviruses but not that of adenoviruses and herpesviruses. J. Virol., 68, 4785-4796.
21. 1 cyclin-dependent kinases. Genes Dev., 9, 1149-1163.
22. 1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J., 13, 3321-3328.
23. Sista,N.D., Pagano,J.S., Liao,W. and Kenney,S. (1993) Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc. Natl Acad. Sci. USA, 90, 3894-3898.
24. Sixbey,J.W., Nedrud,J.G., Raab-Traub,N., Hanes,R.A. and Pagano,J.S. (1984) Epstein-Barr virus replication in oropharyngeal epithelial cells. N. Engl. J. Med., 310, 1225-1230.
25. Sixbey,J.W., Lemon,S.M. and Pagano,J.S. (1986) A second site for Epstein-Barr virus shedding: the uterine cervix. Lancet, ii, 1122-1124.
26. Takimoto,T., Kamide,M. and Umeda,R. (1984) Establishment of Epstein-Barr virus (EBV) associated nuclear antigen (EBNA) positive nasopharyngeal carcinoma hybrid cell line (NPC-KT). Arch. Otor., 239, 87-92.
27. Tomkinson,B., Robertson,E. and Kieff,E. (1993) Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J. Virol., 67, 2014-2025.
28. 1 cyclin-cdk protein kinase activity, is related to p21. Cell, 78, 67-74.
29. Urier,G., Buisson,M., Chambard,P. and Sergeant,A. (1989) The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites. EMBO J., 8, 1447-1453.
30. Vousden,K.H. (1995) Regulation of the cell cycle by viral oncoproteins. Semin. Cancer Biol., 6, 109-116.
31. Werness,B.A., Levine,A.J. and Howley,P.M. (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science, 248, 76-79.
32. Wolf,H., Haus,M. and Wilmes,E. (1984) Persistence of Epstein-Barr virus in the parotid gland. J. Virol., 51, 795-798.
33. Wu,X., Bayle,J.H., Olson,D. and Levine,A.J. (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 7, 1126-1132.
34. Xiong,Y., Hannon,G., Zhang,H., Casso,D., Kobayashi,R. and Beach,D. (1993) p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704.
35. Yates,J.L., Warren,N. and Sugden,B. (1985) Stable replication of plasmids derived from Epstein-Barr virus in a variety of mammalian cells. Nature, 313, 812-815.
36. Young,L.S., Lau,R., Rowe,M., Niedobotek,G., Packham,G., Shanahan,F., Rowe,D.T., Greenspan,D., Greenspan,J.S., Rickinson,A.B. and Farrell,P.J. (1991) Differentiation associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J. Virol., 65, 2868-2874.
37. Zambetti,G.P. and Levine,A.J. (1993) A comparison of the biological activities of wild-type and mutant p53. FASEB J., 7, 855-865.
38. Zhang,Z., Gutsch,D. and Kenney,S. (1994) Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. J. Virol., 14, 1929-1938.